| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 8.50 | 0.01 (+0.12%) | 6.96 - 12.84 | 35.1 thousand (Above Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 8.49 |
|---|---|
| Previous Close | 8.49 |
| Day's Range | 8.47 - 8.70 |
| Market Cap | 127.8M |
| Avg Volume (10 Day) | 11.9K |
| Price/Earnings (Trailing 12 Mo.) | 42.2x |
| Earnings Per Share (Trailing 12 Mo.) | 0.2 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
No news headlines available for GENT
| GENT | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 33.61% | |
| Net Income Growth (1yr) | 3,871.05% | |
| Total Debt/Equity | 0.07 | |
| LT Debt/Equity | 0.05 | |
| Earnings Yield | 2.37% | |
| Price/Sales | 3.10 |
| Company | Last | Change |
|---|---|---|
| Pernix Therapeutics Holdings Inc | 3.68 | +2.22% |
| MEI Pharma Inc | 8.22 | -1.20% |
| POZEN Inc | 5.10 | +3.45% |
| Cumberland Pharmaceuticals Inc | 4.91 | +3.37% |
| DURECT Corp | 0.85 | -4.15% |
Data is delayed by at least 15 min.